Margetuximab for HER2+ Metastatic Breast Cancer Falls Short Margetuximab for HER2+ Metastatic Breast Cancer Falls Short

With such a small improvement in progression-free survival, margetuximab is ' simply not enough ' for advanced HER2+ breast cancer, says Dr Kathy Miller.Medscape Oncology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news